FDA MedWatch – Important drug warnings for Humira (adalimumab)

FDA MedWatch – Important drug warnings for Humira (adalimumab) MedWatch – The FDA Safety Information and Adverse Event Reporting Program FDA and Abbott Pharmaceuticals notified healthcare professionals of revisions to the

WARNINGS section of the prescribing information, indicated for the treatment of rheumatoid arthritis. These warnings include serious infections with the combined use of Humira (adalimumab) and anakinra, hypersensitivity reactions, including anaphylaxis, and hematologic events, including pancytopenia and aplastic anemia. Read the MedWatch 2004 safety summary, including links to the "Dear Healthcare Professional" letter and the revised label, at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Humira

1 Star2 Stars3 Stars4 Stars5 Stars (145 votes, average: 3.10 out of 5)

Leave a Reply